Germany
· Delayed Price · Currency is EUR Vertex Pharmaceuticals Statistics
Total Valuation
FRA:VX1 has a market cap or net worth of EUR 113.73 billion. The enterprise value is 105.33 billion.
| Market Cap | 113.73B |
| Enterprise Value | 105.33B |
Important Dates
The next estimated earnings date is Monday, May 5, 2025.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.00% |
| Shares Change (QoQ) | -0.19% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 256.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.68 |
| PB Ratio | 7.18 |
| P/TBV Ratio | 8.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.14, with an EV/FCF ratio of -137.98.
| EV / Earnings | -203.60 |
| EV / Sales | 10.78 |
| EV / EBITDA | 24.14 |
| EV / EBIT | 25.86 |
| EV / FCF | -137.98 |
Financial Position
The company has a current ratio of 2.69, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.69 |
| Quick Ratio | 2.17 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.36 |
| Debt / FCF | -2.21 |
| Interest Coverage | 150.08 |
Financial Efficiency
Return on equity (ROE) is -3.15% and return on invested capital (ROIC) is 15.71%.
| Return on Equity (ROE) | -3.15% |
| Return on Assets (ROA) | 12.68% |
| Return on Invested Capital (ROIC) | 15.71% |
| Return on Capital Employed (ROCE) | 24.21% |
| Revenue Per Employee | 1.74M |
| Profits Per Employee | -84,809 |
| Employee Count | 6,100 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 5.14 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.52% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +20.52% |
| 50-Day Moving Average | 448.95 |
| 200-Day Moving Average | 437.20 |
| Relative Strength Index (RSI) | 54.06 |
| Average Volume (20 Days) | 193 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.92 |
Income Statement
In the last 12 months, FRA:VX1 had revenue of EUR 10.64 billion and -517.34 million in losses. Loss per share was -2.01.
| Revenue | 10.64B |
| Gross Profit | 5.82B |
| Operating Income | 4.44B |
| Pretax Income | 240.03M |
| Net Income | -517.34M |
| EBITDA | 4.61B |
| EBIT | 4.44B |
| Loss Per Share | -2.01 |
Balance Sheet
The company has 5.91 billion in cash and 1.69 billion in debt, giving a net cash position of 9.15 billion.
| Cash & Cash Equivalents | 5.91B |
| Total Debt | 1.69B |
| Net Cash | 9.15B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 15.85B |
| Book Value Per Share | 61.69 |
| Working Capital | 5.83B |
Cash Flow
In the last 12 months, operating cash flow was -475.80 million and capital expenditures -287.55 million, giving a free cash flow of -763.35 million.
| Operating Cash Flow | -475.80M |
| Capital Expenditures | -287.55M |
| Free Cash Flow | -763.35M |
| FCF Per Share | n/a |
Margins
Gross margin is 54.67%, with operating and profit margins of 41.67% and -4.86%.
| Gross Margin | 54.67% |
| Operating Margin | 41.67% |
| Pretax Margin | 2.25% |
| Profit Margin | -4.86% |
| EBITDA Margin | 43.33% |
| EBIT Margin | 41.67% |
| FCF Margin | n/a |
Dividends & Yields
FRA:VX1 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.00% |
| Shareholder Yield | 1.00% |
| Earnings Yield | -0.45% |
| FCF Yield | -0.67% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:VX1 has an Altman Z-Score of 13.47.
| Altman Z-Score | 13.47 |
| Piotroski F-Score | n/a |